IP Library Granted Patent US 7,754,725
Granted Patent B2
US 7,754,725 · App. 11/680,818 · Granted Jul 13, 2010

Dihydroxyphenyl isoindolymethanones

Assignee: Astex Therapeutics Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,754,725
App. No.
11/680,818
Granted
Jul 13, 2010
Kind
B2
Abstract

Compounds having the formula (I): and in particular, those of subgenus VIIa are disclosed as inhibits or modulators of the activity of the heat shock protein Hsp90. As such they are useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate cancer, lung cancer, gastrointestinal stromal tumor, breast cancer and melanoma.

Claims (18)

1. A compound chosen from the group consisting of:

or a salt or hydrate thereof.

2. (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone

or a salt or hydrate thereof, according to claim 1 .

3. (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-yl)-1,3-dihydro-isoindol-2-yl]-methanone

or a salt or hydrate thereof, according to claim 1 .

4. (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(4-hydroxy-1-methyl-piperidin-4-yl)-1,3-dihydro-isoindol-2-yl]-methanone

or a salt or hydrate thereof, according to claim 1 .

5. (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindol-2-yl]-methanone

or a salt or hydrate thereof, according to claim 1 .

6. (2,3-Dihydroxy-5-isopropyl-phenyl)-[5-(1-methyl-piperidin-4-ylamino)-1,3-dihydro-isoindol-2-yl]-methanone

or a salt or hydrate thereof, according to claim 1 .

7. (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(piperazin-1-yl)-1,3-dihydro-isoindol-2-yl]-methanone

or a salt or hydrate thereof, according to claim 1 .

8. (2,4-Dihydroxy-5-isopropyl-phenyl)-(5-dimethylaminomethyl-1,3-dihydro-isoindol-2-yl)-methanone

or a salt or hydrate thereof, according to claim 1 .

9. A pharmaceutical composition comprising a compound, or a salt or hydrate thereof, according to claim 1 and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition according to claim 9 wherein said pharmaceutically acceptable carrier is a carrier for intravenous or oral administration.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jun 8, 2010
From: OXFORD FINANCE CORPORATION
To: ASTEX THERAPEUTICS, LIMITED
Reel/Frame 024504/0333 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2008
From: CHESSARI, GIANNI; CARR, MARIA GRAZIA; CONGREVE, MILES STUART; FREDERICKSON, MARTYN; MURRAY, CHRISTOPHER WILLIAM; NAVARRO, EVA FIGUEROA; O'BRIEN, MICHAEL ALISTAIR; WOODHEAD, ANDREW JAMES; DOWNHAM, ROBERT; PHILLIPS, THERESA RACHEL
To: ASTEX THERAPEUTICS LTD.
Reel/Frame 020844/0404 →
DEBENTURE Recorded Feb 19, 2008
From: ASTEX THERAPEUTICS LIMITED
To: OXFORD FINANCE CORPORATION
Reel/Frame 020526/0490 →
Continuity (2)
Provisional Application 6077798900 · Mar 1, 2006
Related Publication 20070259886A1 · Nov 8, 2007